Urogen Pharma Ltd. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Urogen Pharma Ltd. on September 13, 2024, regarding an event that occurred on September 12, 2024. The Company is incorporated in Israel and its ordinary shares trade on The Nasdaq Stock Market LLC under the symbol URGN.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On September 12, 2024, Fred E. Cohen, M.D., D.Phil., resigned as a director of the Company, effective immediately. The Company stated that Dr. Cohen's resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the specific event of the director's departure.
Key Facts for Investor Verification
- Dr. Fred E. Cohen resigned from the Board of Directors effective September 12, 2024.
- The resignation was not caused by any disagreement with the Company regarding operations or policies.
- The report was signed by Don Kim, Chief Financial Officer, on September 13, 2024.